Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

April 10, 2024

https://www.prnewswire.com/news-releases/scinai-to-showcase-its-novel-biological-local-therapeutic-for-plaque-psoriasis-at-dermatology-drug-development-summit-together-with-prof-michael-schon-of-umg-302112977.html

JERUSALEM, April 10, 2024 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that the company’s Chief Science Officer, Dr. Tamar Ben-Yedidia, and the University Medical Center Göttingen’s Director, Department of Dermatology, Venereology & Allergology, Prof. Michael Schön, will be presenting together at the upcoming 5th Dermatology Drug Development Summit Europe, which will take place in Berlin between April 16-18, 2024. Their presentation will cover the use of Scinai’s NanoAbs as a local treatment for plaque psoriasis. In addition, Scinai’s CEO, Mr. Amir Reichman will be panel participant in the panel discussion titled: “Route of Administration & Formulations: How Can We Improve?”

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.